Redirecting Immune Memory from Pathogens or Childhood Vaccines to Target Cancer
Washington, USA
Joined January 2020
- Tweets23
- Following10
- Followers17
- Likes19
we're excited to bring on over $3M in additional capital! This funding will enable VerImmune to continue advancing our lead VERI-101 program using the guidance and feedback from our FDA pre-IND meeting earlier this year! prnewswire.com/news-releases…
Interested in seeing something truly differentiated? Swing by @VerImmune_’s company presentation at #BIO2023 ! At 115pm , Room 104A ! #platform #platform-therapeutics
79
VerImmune Announces Positive Pre-IND Meeting with FDA! Favorable feedback and clear development path for VERI-101, a novel Immunotherapy secured! prn.to/3q38Tyz
VerImmune Awarded $500K SBIR Phase IIB Follow-on Funding from the National Science Foundation!! linkedin.com/posts/verimmune…
VerImmune accepted into the Nanotechnology Characterization Laboratory at the Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute story.cd/AATvBL
VerImmune Closes USD2.5M in Seed Financing - FinSMEs finsmes.com/2022/07/verimmun…
VerImmune raises $2.5M to develop virus-inspired particle immunotherapies labiotech.eu/trends-news/ver… via @Labiotech_eu
VerImmune retweeted
Congratulations to the @VerImmune_ team! @uluventures is proud to be supporters of your mission to develop new therapeutic modalities to redirect the body's pre-existing immunity toward cancer. #biotech #research #pharmaceutical
VerImmune is pleased to announce the close of it's Seed Financing Round! This was led by SeedFolio VC with participation from ProximaVC, @UluVentures, @NuFundventures, @GaingelsVC, ManaVentures and others! story.cd/AATpyw
VerImmune retweeted
Congrats to @JLABS Washington, DC resident @VerImmune on their recent $2.5M Seed funding announcement. The funding will allow them to further accelerate VerImmune’s lead product development and expand their team. #immunooncology #oncology #funding #jlabsdc
VerImmune is pleased to announce the close of it's Seed Financing Round! This was led by SeedFolio VC with participation from ProximaVC, @UluVentures, @NuFundventures, @GaingelsVC, ManaVentures and others! story.cd/AATpyw
VerImmune is pleased to announce the close of it's Seed Financing Round! This was led by SeedFolio VC with participation from ProximaVC, @UluVentures, @NuFundventures, @GaingelsVC, ManaVentures and others! story.cd/AATpyw
Congratulations to our collaborators & advisors at NCI for their stellar publication in PNAS!! Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors | Proceedings of the National Academy of Sciences pnas.org/doi/10.1073/pnas.21…
VerImmune and Fosun Pharma enter into an Exclusive License and Option Agreement for VerImmune’s Virus-inspired Particle (ViP) platform as Novel Immunotherapies in China story.cd/AATEVW via @PRWeb
2
VerImmune, Inc. Announces Issuance of U.S Patent Protecting Proprietary Technology Platform story.cd/AASoDd
We are excited too! Looking forward to making a difference!
I’m excited to share a recent collaboration facilitated by @JNJInnovation between @JanssenGlobal and @VerImmune_, a @JLABS Washington DC resident, that will explore an innovative immuno-oncology platform to target #cancer.
prweb.com/releases/verimmune…
VerImmune retweeted
We’re excited to share a collaboration between @JanssenGlobal and @VerImmune_ that will explore an innovative immuno-oncology platform to target #cancer.
Learn more how this R&D will progress:
bit.ly/3szlaIO
VerImmune retweeted
Congratulations to CEO Joshua Weiyuan Wang of @VerImmune, a @JLABS Washington DC resident, on their recent collaboration with @JanssenGlobal facilitated by @JNJInnovation, that aims to progress an innovative immuno-oncology platform to target #cancer #jlabsdc
VerImmune Inc Announces Research Collaboration with Janssen to Leverage its Unique Immuno-oncology Therapeutic Platform story.cd/AASP1f via @PRWeb
VerImmune Inc Announces Research Collaboration with Janssen to Leverage its Unique Immuno-oncology Therapeutic Platform story.cd/AASP1f via @PRWeb
@VerImmune_ Inc has secured a follow-on @NSFSBIR Phase II award worth $700K. The funds will further the development of VerImmune’s novel first-in-class broad spectrum cancer immunotherapy platform for solid tumors #immunotherapy #nsffunded #SBIR #AIRs verimmune.com/news/verimmune…
Come learn about how we intend to repurpose our immune memory against childhood vaccines or past infections against cancer at the #Biotechshowcase today! Wed, Jan 15, 2020 at 10:30 a.m. PST Yosemite A (Ballroom Level) #JPM20 #JPM2020 #BroadenTreatmentOpportunities
